RAF1 (R391W)
Sign in to save this workspaceRAF1 · Variant type: point · HGVS: p.R391W
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ripretinib | 100.0% | 0.0% | 92.95 |
| 2 | Sorafenib | 100.0% | 0.0% | 96.72 |
| 3 | Umbralisib | 99.9% | 0.1% | 98.74 |
| 4 | Apatinib | 99.8% | 0.2% | 97.73 |
| 5 | Upadacitinib | 98.6% | 1.4% | 97.98 |
| 6 | Rabusertib | 98.1% | 1.9% | 98.74 |
| 7 | Tivozanib | 82.0% | 18.0% | 92.42 |
| 8 | Erdafitinib | 60.0% | 40.0% | 95.71 |
| 9 | Paxalisib | 54.0% | 46.0% | 99.75 |
| 10 | Repotrectinib | 37.1% | 62.9% | 84.21 |
| 11 | Gedatolisib | 22.0% | 78.0% | 99.75 |
| 12 | Vandetanib | 20.3% | 79.7% | 95.74 |
| 13 | Pexidartinib | 20.2% | 79.8% | 99.49 |
| 14 | Quizartinib | 16.5% | 83.5% | 99.50 |
| 15 | Alpelisib | 16.2% | 83.8% | 97.22 |
| 16 | Tenalisib | 15.5% | 84.5% | 97.98 |
| 17 | Selpercatinib | 15.2% | 84.8% | 96.72 |
| 18 | Pacritinib | 14.9% | 85.1% | 88.64 |
| 19 | Infigratinib | 12.7% | 87.3% | 98.24 |
| 20 | Leniolisib | 12.5% | 87.5% | 100.00 |
| 21 | Acalabrutinib | 12.4% | 87.6% | 99.50 |
| 22 | Pralsetinib | 11.2% | 88.8% | 93.43 |
| 23 | Cobimetinib | 10.7% | 89.3% | 100.00 |
| 24 | Abrocitinib | 9.9% | 90.1% | 99.50 |
| 25 | Capivasertib | 9.7% | 90.3% | 96.48 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ripretinib | 100.0% | 100.0% | +0.0% |
| Sorafenib | 100.0% | 100.0% | +0.0% |
| Umbralisib | 99.9% | 99.8% | +0.1% |
| Apatinib | 99.8% | 100.0% | -0.2% |
| Upadacitinib | 98.6% | 99.9% | -1.3% |
| Rabusertib | 98.1% | 95.6% | +2.4% |
| Tivozanib | 82.0% | 67.6% | +14.4% |
| Erdafitinib | 60.0% | 61.4% | -1.5% |
| Paxalisib | 54.0% | 54.2% | -0.1% |
| Repotrectinib | 37.1% | 51.6% | -14.4% |
| Gedatolisib | 22.0% | — | — |
| Vandetanib | 20.3% | — | — |
| Pexidartinib | 20.2% | — | — |
| Quizartinib | 16.5% | — | — |
| Alpelisib | 16.2% | — | — |
| Tenalisib | 15.5% | — | — |
| Selpercatinib | 15.2% | — | — |
| Pacritinib | 14.9% | — | — |
| Infigratinib | 12.7% | — | — |
| Leniolisib | 12.5% | — | — |
| Acalabrutinib | 12.4% | — | — |
| Pralsetinib | 11.2% | — | — |
| Cobimetinib | 10.7% | — | — |
| Abrocitinib | 9.9% | — | — |
| Capivasertib | 9.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoid-endocrine_tumour_lung | Lung | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| malignant_melanoma_skin | Skin | ref |
| CLLE-ES | Blood/Lymphatic System | ref |
| KIRP-US | Kidney | ref |
| KIRP | Kidney | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.5ms